The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
|Videos|August 21, 2020
Dr. Garon on the Expanding Treatment Landscape in Lung Cancer
Author(s)Edward B. Garon, MD
Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.
Advertisement
Edward B. Garon, MD, associate professor of medicine, David Geffen School of Medicine, University of California, Los Angeles, discusses the expanding treatment landscape in lung cancer.
In recent years, several immune checkpoint inhibitors have been approved in the lung cancer space, including the combination of ipilimumab (Yervoy) and nivolumab (Opdivo), says Garon.
Moreover, several targeted therapies, such as RET and MET exon 14 skipping TKIs, have further expanded the armamentarium, Garon concludes.
Advertisement
Related to this article
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5